The success of targeting kinases in cancer with small molecule inhibitors has been
tempered by the emergence of drug-resistant kinase domain mutations. In patients with …

In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is
associated with point mutations in the BCR-ABL kinase domain. A new generation of potent …

Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-
positive leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome …

Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the
BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia …

Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and
effectively controlling diseases driven by this kinase. IM resistance has been associated with …

Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that
specifically inhibits the BCR–ABL tyrosine kinase activity in patients with Philadelphia …

Disease relapse in CML patients treated with imatinib is often associated with mutations in
the BCR-ABL gene that interfere with the ability of imatinib to block BCR-ABL kinase activity …

Background: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor Imatinib mesylate
for the treatment of chronic myeloid leukemia (CML), resistance has been observed in a …

Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …

The emergence of resistance to imatinib has become a significant problem despite the
remarkable clinical results achieved with this tyrosine kinase inhibitor in the treatment of …